--- title: "Beam Therapeutics | 10-K: FY2025 Revenue Beats Estimate at USD 139.74 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/276731342.md" datetime: "2026-02-24T12:13:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276731342.md) - [en](https://longbridge.com/en/news/276731342.md) - [zh-HK](https://longbridge.com/zh-HK/news/276731342.md) generator: "portal-rs" --- # Beam Therapeutics | 10-K: FY2025 Revenue Beats Estimate at USD 139.74 M Revenue: As of FY2025, the actual value is USD 139.74 M, beating the estimate of USD 38.5 M. EPS: As of FY2025, the actual value is USD -0.81, beating the estimate of USD -4.3127. #### Net Loss Beam Therapeutics Inc. reported net losses of - $80.0 million for 2025, - $376.7 million for 2024, and - $132.5 million for 2023 . #### Accumulated Deficit As of December 31, 2025, Beam Therapeutics Inc. had an accumulated deficit of - $1.6 billion . #### Cash, Cash Equivalents, and Marketable Securities As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $1.2 billion . #### Collaboration Payments and Milestones - **Lilly Agreement:** Beam Therapeutics Inc. received a $200.0 million payment and is eligible for up to $350.0 million in future development-stage payments, with $25.0 million received through December 31, 2025 . No milestone payments were received in 2025 . - **Orbital Therapeutics Acquisition:** The company received $255.1 million in closing cash consideration from Bristol-Myers Squibb Company’s acquisition of Orbital Therapeutics Inc., with the right to receive up to an additional $26.3 million from escrows . - **Harvard License Agreement:** Beam Therapeutics Inc. paid Harvard $9.0 million upon Series A and Series B financings . A $15.0 million success payment was due in May 2021 and settled with 174,825 shares of common stock . Up to an additional $90.0 million in success payments may be owed to Harvard . - **Editas License Agreement:** An upfront fee of $180,000 was paid, along with the issuance of 1,833,333 shares of Series A-1 Preferred Stock and 1,222,222 shares of Series A-2 Preferred Stock . Aggregate milestone payments could reach up to $68.8 million per product using base editing and CRISPR technology, and up to $74.0 million per product for additional licensed patent families . Sublicense income owed ranges from none to 10-20% . - **Bio Palette License Agreement:** An upfront fee of $0.5 million was paid, and 16,725 shares of common stock were issued . A $2.0 million milestone payment was made in June 2020 upon patent issuance, and 175,000 shares of common stock valued at $0.3 million were issued in July 2020 . A fraction of a percent royalty is payable on net sales of covered products . - **Apellis Pharmaceuticals:** An opt-in fee of $3.8 million was received as of September 30, 2025, for the FcRN base editing program . #### Credit Facility On February 24, 2026, Beam Therapeutics Inc. entered into a $500.0 million senior secured term loan facility with Sixth Street Lending Partners, including $100.0 million funded at closing, up to $300 million tied to risto-cel milestones, and an optional $100 million . #### Workforce and Operational Metrics As of December 31, 2025, Beam Therapeutics Inc. had 511 full-time team members, with 399 in research and development and 112 in general and administrative roles . 118 team members held an M.D. or Ph.D. degree . The company aims for an annual employee retention rate greater than 85% and an internal engagement survey participation rate greater than 90% . #### Intellectual Property Portfolio As of December 31, 2025, Beam Therapeutics Inc. held 12 wholly-owned issued U.S. patents, 57 issued international patents, and over 550 pending patent applications . It also had over 75 in-licensed issued U.S. patents, over 150 issued international patents, and over 300 pending patent applications . Additionally, there were 35 registered/allowed trademarks and pending applications in the U.S. and overseas . #### Outlook / Guidance Beam Therapeutics Inc. expects to submit a BLA for risto-cel as early as year-end 2026 and to complete dosing for the BEAM-103 clinical trial in the first half of 2026 . The company plans to report updated BEAM-302 data and next steps for pivotal development by the end of Q1 2026 . Furthermore, a regulatory application for BEAM-304 is anticipated in 2026 to initiate a Phase 1⁄2 trial, with initial clinical data for BEAM-301 also expected in 2026 . ### Related Stocks - [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md) ## Related News & Research - [BEAM: BEAM-302 shows durable efficacy and safety in AATD, advancing toward accelerated approval](https://longbridge.com/en/news/298312291.md) - [Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment](https://longbridge.com/en/news/298328225.md) - [Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results](https://longbridge.com/en/news/295256769.md) - [Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 5.8% - What's Next?](https://longbridge.com/en/news/296937626.md) - [Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary](https://longbridge.com/en/news/294814748.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**